• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli.人源化哌拉西林-他唑巴坦暴露量与哌拉西林-他唑巴坦耐药/泛β-内酰胺敏感大肠埃希菌的体外-体内不一致性
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7527-7529. doi: 10.1128/AAC.01208-16. Print 2016 Dec.
2
Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Klebsiella pneumoniae Strains.针对哌拉西林-他唑巴坦耐药/泛β-内酰胺敏感肺炎克雷伯菌菌株，人源化哌拉西林-他唑巴坦暴露的不一致性
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00491-17. Print 2017 Jul.
3
In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products.哌拉西林/他唑巴坦的体内药效学：对创新药和仿制药的抗菌疗效和耐药抑制的影响。
Int J Antimicrob Agents. 2017 Feb;49(2):189-197. doi: 10.1016/j.ijantimicag.2016.10.011. Epub 2016 Nov 23.
4
Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance.哌拉西林-他唑巴坦耐药/第三代头孢菌素敏感的大肠埃希菌和肺炎克雷伯菌分离株：耐药机制和体外-体内不相符。
Int J Antimicrob Agents. 2020 Mar;55(3):105885. doi: 10.1016/j.ijantimicag.2020.105885. Epub 2020 Jan 8.
5
In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.在体内比较 CXA-101（FR264205）与他唑巴坦联用和不联用哌拉西林-他唑巴坦对表型多样的革兰氏阴性菌的模拟人体暴露效果。
Antimicrob Agents Chemother. 2012 Jan;56(1):544-9. doi: 10.1128/AAC.01752-10. Epub 2011 Nov 7.
6
Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.他唑巴坦药代动力学对哌拉西林-他唑巴坦联合用药抗菌效果的影响。
Int J Antimicrob Agents. 2004 May;23(5):494-7. doi: 10.1016/j.ijantimicag.2003.10.012.
7
Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.希腊一家三级护理医院实施限制政策后，肺炎克雷伯菌和大肠埃希菌临床分离株对第三代和第四代头孢菌素以及哌拉西林/他唑巴坦耐药模式变化的差异。
Int J Antimicrob Agents. 2007 Jan;29(1):34-8. doi: 10.1016/j.ijantimicag.2006.08.042.
8
Detection of Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli with Current Automated Susceptibility Test Systems.使用当前自动药敏试验系统检测对哌拉西林-他唑巴坦耐药/对泛β-内酰胺敏感的大肠埃希菌
Infect Control Hosp Epidemiol. 2017 Mar;38(3):379-380. doi: 10.1017/ice.2016.325. Epub 2017 Jan 10.
9
The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.哌拉西林/他唑巴坦的广泛使用对侵袭性大肠埃希菌和肺炎克雷伯菌分离株抗生素耐药性选择的影响。
Int J Infect Dis. 2013 Aug;17(8):e638-43. doi: 10.1016/j.ijid.2013.01.030. Epub 2013 Mar 21.
10
In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.在文献中。哌拉西林-他唑巴坦与产超广谱β-内酰胺酶的大肠埃希菌。
Clin Infect Dis. 2013 Nov;57(10):iii-iv.

引用本文的文献

1
Assessing the in vivo efficacy of rational antibiotics and combinations against difficult-to-treat Pseudomonas aeruginosa producing GES β-lactamases.评估针对产 GES β-内酰胺酶的难治性铜绿假单胞菌的合理抗生素及其联合用药的体内疗效。
J Antimicrob Chemother. 2023 Aug 2;78(8):1843-1847. doi: 10.1093/jac/dkad098.
2
Epidemiology of Bloodstream Infections Caused by and That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible.由对哌拉西林 - 他唑巴坦不敏感但对头孢曲松敏感的[细菌名称未给出]引起的血流感染的流行病学
Open Forum Infect Dis. 2018 Nov 19;5(12):ofy300. doi: 10.1093/ofid/ofy300. eCollection 2018 Dec.
3
Assessment of the Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model.评估 WCK 5222（头孢吡肟-齐他培南）在中性粒细胞减少症小鼠肺部感染模型中对碳青霉烯类耐药鲍曼不动杆菌的疗效。
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.00948-18. Print 2018 Nov.
4
Assessment of the Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model.评估 SPR741 联合阿奇霉素对中性粒细胞减少症小鼠大腿感染模型中多药耐药肠杆菌科分离株的活性。
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00239-18. Print 2018 Jul.
5
Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli.广泛基因扩增作为大肠埃希菌对哌拉西林-他唑巴坦耐药的机制。
mBio. 2018 Apr 24;9(2):e00583-18. doi: 10.1128/mBio.00583-18.
6
Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Klebsiella pneumoniae Strains.针对哌拉西林-他唑巴坦耐药/泛β-内酰胺敏感肺炎克雷伯菌菌株，人源化哌拉西林-他唑巴坦暴露的不一致性
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00491-17. Print 2017 Jul.

本文引用的文献

1
Impact of blaNDM-1 on fitness and pathogenicity of Escherichia coli and Klebsiella pneumoniae.blaNDM-1 对大肠杆菌和肺炎克雷伯菌的适应性和致病性的影响。
Int J Antimicrob Agents. 2016 Jun;47(6):430-5. doi: 10.1016/j.ijantimicag.2016.02.019. Epub 2016 Apr 26.
2
The Pandemic H30 Subclone of Escherichia coli Sequence Type 131 Is Associated With Persistent Infections and Adverse Outcomes Independent From Its Multidrug Resistance and Associations With Compromised Hosts.大肠杆菌序列型131的大流行H30亚克隆与持续性感染及不良结局相关，与其多重耐药性以及与宿主免疫功能受损的关联无关。
Clin Infect Dis. 2016 Jun 15;62(12):1529-1536. doi: 10.1093/cid/ciw193. Epub 2016 Mar 29.
3
Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.头孢洛扎/他唑巴坦及其他胃肠外抗菌药物对美国医院分离的大肠埃希菌、肺炎克雷伯菌和铜绿假单胞菌的药敏谱
Clin Ther. 2015 Jul 1;37(7):1564-71. doi: 10.1016/j.clinthera.2015.05.501. Epub 2015 Jun 15.
4
Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.在中空纤维药效学模型中头孢他啶和阿维巴坦对产β-内酰胺酶肠杆菌科细菌的活性
Antimicrob Agents Chemother. 2014 Jun;58(6):3366-72. doi: 10.1128/AAC.00080-14. Epub 2014 Mar 31.
5
Antibiotic prescription patterns in the empiric therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduces mortality.严重脓毒症经验性治疗中的抗生素处方模式：联合使用具有不同作用机制的抗菌药物可降低死亡率。
Crit Care. 2012 Nov 18;16(6):R223. doi: 10.1186/cc11869.
6
Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.头孢他啶和头孢他啶-阿维巴坦人体模拟剂量对铜绿假单胞菌的体外和体内疗效比较。
Antimicrob Agents Chemother. 2012 Dec;56(12):6137-46. doi: 10.1128/AAC.00851-12. Epub 2012 Sep 17.
7
In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.在体内比较 CXA-101（FR264205）与他唑巴坦联用和不联用哌拉西林-他唑巴坦对表型多样的革兰氏阴性菌的模拟人体暴露效果。
Antimicrob Agents Chemother. 2012 Jan;56(1):544-9. doi: 10.1128/AAC.01752-10. Epub 2011 Nov 7.
8
Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae.产碳青霉烯酶肺炎克雷伯菌的双重碳青霉烯类治疗。
Antimicrob Agents Chemother. 2011 Jun;55(6):3002-4. doi: 10.1128/AAC.01420-10. Epub 2011 Mar 21.
9
In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.模拟人体延长输注美罗培南给药方案对产碳青霉烯酶肺炎克雷伯菌的体内疗效。
Antimicrob Agents Chemother. 2010 Oct;54(10):4112-5. doi: 10.1128/AAC.00026-10. Epub 2010 Jul 26.
10
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.高产率、长时间人模拟输注美罗培南对产 KPC 碳青霉烯酶肺炎克雷伯菌与体外药效动力学模型中铜绿假单胞菌的活性比较。
Antimicrob Agents Chemother. 2010 Feb;54(2):804-10. doi: 10.1128/AAC.01190-09. Epub 2009 Dec 7.

人源化哌拉西林-他唑巴坦暴露量与哌拉西林-他唑巴坦耐药/泛β-内酰胺敏感大肠埃希菌的体外-体内不一致性

In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli.

作者信息

Monogue M L, Nicolau D P

机构信息

Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.

Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA

出版信息

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7527-7529. doi: 10.1128/AAC.01208-16. Print 2016 Dec.

DOI:10.1128/AAC.01208-16
PMID:27799205
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5119043/
Abstract

Recent findings have identified Escherichia coli strains that are pan-β-lactam susceptible (PBL-S) but piperacillin-tazobactam resistant (TZP-R) in vitro We assessed the in vivo significance of this resistance profile in a neutropenic murine pneumonia model using humanized exposures of TZP with 18 clinical E. coli isolates, 8 TZP-S/PBL-S and 10 genotypically confirmed TZP-R/PBL-S. Despite phenotypically and genotypically defined resistance, TZP displayed efficacy against these isolates. Additional studies are required to define the clinical implications of these TZP-R/PBL-S strains.

摘要

最近的研究发现，在体外存在对所有β-内酰胺类药物敏感（PBL-S）但对哌拉西林-他唑巴坦耐药（TZP-R）的大肠杆菌菌株。我们在中性粒细胞减少的小鼠肺炎模型中，使用人源化的哌拉西林-他唑巴坦暴露剂量，对18株临床分离的大肠杆菌进行了评估，其中8株为TZP敏感/PBL敏感，10株经基因分型确认为TZP耐药/PBL敏感。尽管这些菌株在表型和基因型上都表现出耐药性，但哌拉西林-他唑巴坦对它们仍有疗效。需要进一步的研究来明确这些TZP耐药/PBL敏感菌株的临床意义。